Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib

Hao Song; Jinna Zhang; Liang Ning; Honglai Zhang; Dong Chen; Xuelong Jiao; Kejun Zhang

doi:10.12659/MSM.936571

Retracted: The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib

Med Sci Monit. 2022 Mar 7:28:e936571. doi: 10.12659/MSM.936571.

Authors

Hao Song¹, Jinna Zhang², Liang Ning³, Honglai Zhang², Dong Chen³, Xuelong Jiao³, Kejun Zhang²

Affiliations

¹ Department of Radiotherapy, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
² Department of Thyroid Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).
³ Department of General Surgery, The Affiliated Hospital of Qingdao University, Qingdao, Shandong, China (mainland).

Abstract

This publication has been retracted by the Editor due to the identification of falsified figure images and manuscript content that raise concerns regarding the credibility of the study and the manuscript. Reference: Vemurafenib Hao Song, Jinna Zhang, Liang Ning, Honglai Zhang, Dong Chen, Xuelong Jiao, Kejun Zhang. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib. Med Sci Monit, 2018; 24: 3002-3010. DOI: 10.12659/MSM.910084.

Publication types

Retraction of Publication